NCT05846763View on ClinicalTrials.gov

Obinutuzumab in Combination With Lenalidomide in Relapsed or Refractory Follicular Lymphoma in Real World Study

RecruitingOBSERVATIONAL

Enrollment

50

Participants

Timeline

Start Date

November 1, 2022

Primary Completion Date

May 31, 2026

Study Completion Date

May 31, 2028

Conditions

Follicular Lymphoma

Trial Locations (1)

300020

RECRUITING

Institute of Hematology and Blood Diseases Hospital ,Chinese Academy of Medical Sciences, Tianjin

All Listed Sponsors

lead

Institute of Hematology & Blood Diseases Hospital, China

OTHER